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Information on severity of coronavirus disease (COVID-
19) (transmissibility, disease seriousness, impact) is 
crucial for preparation of healthcare sectors. We pre-
sent a simple approach to assess disease seriousness, 
creating a reference cohort of pneumonia patients 
from sentinel hospitals. First comparisons exposed 
a higher rate of COVID-19 patients requiring ventila-
tion. There were more case fatalities among COVID-19 
patients without comorbidities than in the reference 
cohort. Hospitals should prepare for high utilisation of 
ventilation and intensive care resources.
As severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) spreads globally, crucial informa-
tion on severity of the epidemic is needed. According 
to the World Health Organization (WHO) guideline 
on Pandemic Influenza Severity Assessment, sever-
ity indicators would be transmissibility, disease seri-
ousness and impact [1]. Transmissibility reflects the 
movement of the virus, which is influenced by the 
dynamics of the spread, the R0 and the susceptibility of 
the exposed population. So far, several estimates on 
R0  exist, ranging between 1.4 to 6.49, which indicate 
a higher transmissibility than seasonal influenza, and 
even higher than SARS-CoV [2]. Impact reflects the 
impact on the healthcare sector, such as capacity uti-
lisation of general practitioners, hospitals and public 
health authorities, and on society. Given the current 
data, the impact in countries other than China is hard 
to assess, although potentially high [3,4]. Disease 
seriousness reflects the extent of individual sickness 
including clinical symptoms, complications and out-
comes. Recent publications from the area first affected 
in China (the city of Wuhan in the province of Hubei) 
offer valuable, although preliminary, data such as the 
proportion of hospitalised coronavirus disease (COVID-
19) patients treated in intensive care units (ICU), ven-
tilated or deceased. These are important parameters 
for the assessment of individual disease seriousness. 
However, a challenge is to apply these data to the 
situation in Europe, given the different population 
structures and comorbidities.
We want to introduce the concept of using syndromic 
surveillance data to assess disease seriousness of 
COVID-19, directly relating the results from clinical stud-
ies and case series on COVID-19 pneumonia patients to 
the situation as it is observed in pneumonia patients at 
the beginning of seasonal influenza epidemics.
 
Concept
With a simple approach, we give a preliminary assess-
ment of individual seriousness of COVID-19 using 
well-described case series of hospitalised COVID-19 
pneumonia patients from the cities of Wuhan, Beijing, 
Shenzhen and the provinces of Hubei and Zhejiang 
[5-12]. We defined a reference group from a well-known 
setting: in 73 German sentinel hospitals, we extracted 
the data of all inpatients diagnosed with pneumonia 
(International Classification of Diseases, 10th revision 
codes J12-J18, primary diagnosis [13]) that were admit-
ted during three consecutive weeks, after the start and 
before the peak of the influenza epidemic in the years 
2015 to 2019. We compared severity parameters that 
were described for COVID-19 patients (acute respiratory 
distress syndrome, ventilation, intensive care, case 
fatality) with those from the German sentinel system. 
Furthermore, we stratified parameters by potential 
risk groups such as age, sex and chronic comorbidi-
ties. We also compared outcomes and risk factors for 
critically ill patients (i.e. received intensive care and 
ventilation) [14]. As the Chinese population is younger, 
with a larger proportion of males compared with the 
German population, we applied weights and provided 
crude and adjusted proportions for the sentinel pneu-
monia patients (SPP) [15]. This approach, which can be 
used by other countries using syndromic surveillance, 
attempts to replicate the uncertainty of initial results 
for the new coronavirus.
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Demographics, comorbidities and outcomes
Crude and adjusted values of mean and median age 
were lower in all COVID-19 case series compared with 
SPP (Table). The proportion of females differed between 
the case series, ranging from 32% in Wuhan to 59% in 
Zhejiang. The adjusted SPP showed a range from 39% 
to 42% in the proportions of females throughout the 
5 years under consideration. The overall proportion of 
comorbidities was much smaller in the COVID-19 case 
series (range: 20–51%) than in German patients, where 
the proportion ranged from 70% to 77%, depending 
on the year. Hypertension and diabetes were the most 
important chronic comorbidities both among COVID-19 
patients and among SPP. However, there were fewer 
patients with chronic obstructive pulmonary disease 
(COPD) or renal disease among COVID-19 patients than 
among SPP. 
Intensive care unit
The proportion of ICU patients in the SPP was 20%, 
ranging from 18% in 2016 to 22% in 2019. This was the 
same scale as described in two case series from Wuhan 
in the province of Hubei [5,6]. However, the case series 
from provinces outside of Hubei reported only 11%, 
Table
Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and 
COVID-19 case series
Characteristics
SPP, crude SPP, adjusted COVID-19
Weeks 3–5, 
2015–19
Weeks 
3–5, 
2015–19
20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days
Wuhan 
[ 5 ]
Wuhan 
[ 6 ]
Wuhan 
[ 7 ]
Hubei 
[ 10 ]
Beijing 
[ 8 ]
Shenzhen 
[ 9 ]
Zhejiang 
[ 11 ]
Zhejiang 
[ 12 ]
Number 5,829 NA 99 138 82 137 262 298 62 91
Mean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA
Median age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50
Female, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59
Any chronic disease, % 
(range) 82 (80–85)
74 
(70–77) 51 46 NA 20 NA 32 32 NA
Hypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16
Endocrine condition/diabetes, 
% (range) 28 (26–30)
24 
(22–26) 13 14 NA 10 NA 6 2 9
COPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA
Cancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA
Renal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA
Liver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA
Of total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA
Of total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA
Of total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10
Of ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA
Of ICU: median age in years 
(range) 76 (74–78)
67 
(64–68) NA 66 NA NA NA NA NA NA
Of ICU: without chronic, % 
(range) 10 (7–12)
16 
(10–19) NA 28 NA NA NA NA NA NA
Of total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0
Of deceased: median age, in 
years (range) 83 (82–84)
78 
(76–79) NA NA 72.5 NA NA NA NA NA
Of deceased: < 60 years, % 
(range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA
Of deceased: without chronic 
disease, % (range) 13 (13–15)
13 
(12–14) 18 NA 23 NA 30 NA NA NA
Still hospitalised, % 58 62 NA 56 82 77 98 66
ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care 
unit; NA: not available; SPP: sentinel pneumonia patients.
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10% and 2% (one case) of ICU patients among COVID-
19 cases, which is remarkably lower [9,11,12]. This may 
be attributed to the preliminary character of the out-
come, as more than half of the cases were still hospi-
talised in these case series (Table and Figure 1).
Among ICU patients, the proportion of males and the 
median age were strikingly similar between COVID-19 
(61% and 66 years) and SPP (61% and 67 years) [6]. 
However, the proportions of chronic comorbidities were 
different: 28% of COVID-19 patients treated on the ICU 
did not have any reported comorbidity, whereas only 
16% of German ICU patients were without comorbidi-
ties (Table).
Ventilation
Three case series from the province Hubei described 
a high rate of cases who needed ventilation (20%, 
23% and 25%) [5,6,10]. German pneumonia patients 
had a two- to threefold lower ventilation rate of 9%. 
The two case series from Shenzhen and the province 
Zhejiang also reported much lower ventilation rates of, 
respectively, 11% and 2% [9,11] (Figure 2). The median 
duration of ventilation was 9 days (interquartile range: 
7–19, n = 13) for non-invasive and 17 days (interquar-
tile range: 12–19, n = 4) for invasive ventilation in the 
COVID-19 case series described by Chen et al. [5]. In 
contrast, the median ventilation duration (invasive 
and non-invasive) in SPP was only 2 days (interquartile 
range: 1–4, n = 303). The high ventilation rates and the 
long duration of ventilation (data from one case series) 
can be attributed to a high rate of acute respiratory 
distress syndrome (ARDS) among COVID-19 patients. 
Again, the difference between Hubei (17–20% ARDS) 
and outside of Hubei (2–4% ARDS) is striking. However, 
ARDS was observed in only 1% of SPP.
Case fatality
The observed case fatality ratios in the described case 
series from Hubei (including the city of Wuhan) ranged 
from 4% to 12%. Most case series outside Hubei did 
not report fatalities. One case series had 1% case 
fatality. However, more than two thirds of the cases 
reported from outside Hubei were still hospitalised 
at the reporting dates. The case fatality ratio among 
SPP was 6%, which is within the range of the reported 
COVID-19 case fatalities (Figure 3). 
A study by Yang et al. described clinical courses and 
outcomes of 52 critically ill patients in a hospital in 
Wuhan [14]. Among 25 critically ill COVID-19 patients 
younger than 60 years, 12 died within 28 days after 
admission to the ICU. Of 31 patients without chronic ill-
nesses, 15 died, which is a comparable proportion of 
almost half.
In the sentinel hospitals, we identified 462 pneumo-
nia patients who were critically ill (i.e. received inten-
sive care and ventilation). Of those patients, 92 were 
younger than 60 years, of whom 12 (13%) died. In addi-
tion, 18 of the critically ill pneumonia patients were 
without chronic preconditions and four of them died.
Discussion
Considering the 5 years from 2015 to 2019, the pro-
portion of severe cases requiring intensive care and 
the case fatality ratios were strikingly similar among 
COVID-19 and German pneumonia patients. However, 
based on these data, COVID-19 may affect a younger 
cohort, which seems not fully explained by the dif-
ferent age structure of the Chinese population. As 
reported by the China Centre for Disease Control and 
Prevention, there seems to be a higher risk for severe 
disease in older ages and in patients with chronic 
Figure 1
Reported proportions of patients in intensive care and 
proportions of patients who were still hospitalised, five 
COVID-19 case series, China, January–February 2020 
(n = 688)
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COVID-19: coronavirus disease; ICU: intensive care unit.
Grey line: proportion of ICU in pneumonia sentinel patients. Data 
from five COVID-19 series [5,6,9,11,12].
Figure 2
Reported proportions of patients on ventilation and 
proportions of patients who were still hospitalised, five 
COVID-19 case series, China, January–February 2020 
(n = 734)
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COVID-19: coronavirus disease.
Grey line: proportion of ventilation in pneumonia sentinel patients. 
Data from five COVID-19 series [5,6,9-11].
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illnesses [16]. But severity in younger adults below 
60 years and in patients without chronic precondi-
tions appears to be higher in COVID-19 patients than in 
pneumonia patients usually seen during the influenza 
season. The rate of ARDS and of patients requiring ven-
tilation was markedly higher among COVID-19 patients 
with much longer duration of ventilation, based in the 
data from one study. During the influenza pandemic 
2009 however, specialised German hospitals reported 
similarly long ventilation duration times [17].
The case series from outside Hubei report much milder 
symptoms than those reported from Hubei, especially 
from Wuhan, which may be due to early admittance 
of contact persons and of suspected cases with only 
mild symptoms. In addition, the large impact on the 
health system in the initially affected province resulted 
in insufficient healthcare resources [3]. This may have 
inhibited adequate treatment as the strikingly higher 
case fatality indicates [18]. However, all COVID-19 case 
series were still open with more than half of the cases 
hospitalised at reporting date. It is known that COVID-
19 cases can have a prolonged course with many fatali-
ties occurring 3 weeks after symptom onset [19]. Case 
fatality rates from these COVID-19 case series can 
therefore only be seen as preliminary.
Moreover, variations in health systems that could result 
in over- or underdiagnosis of chronic comorbidities 
such as COPD [20,21] are unaccounted for and may con-
tribute to some of the observed differences between 
COVID-19 and SPP.
Conclusion
Our approach is flexible enough to create reference 
cohorts, which will allow estimation of COVID-19 
severity using known characteristics and outcomes. As 
more data on European cases are published, the sys-
tem can be applied to cases with a more comparable 
background. First comparisons expose the high rate of 
patients requiring ventilation over prolonged time peri-
ods, thus hospital resources may be in higher demand 
of ventilation supply than usual. In fact, Liu et al. sug-
gests that early non-invasive mechanical ventilation 
can promote positive outcomes [9]. This can only be 
implemented if hospitals prepare for high utilisation 
of ventilation and intensive care resources. Although 
fatalities occur mostly among elderly people with 
chronic comorbidities, serious disease progressions 
do also occur among younger, healthy patients and 
more often than would be expected from the experi-
ence during influenza epidemics.
Editorial note
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